Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 26:ciac416. doi: 10.1093/cid/ciac416

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2022. This work is written by (a) US Government employee(s) and is in the public domain in the US.

This work is written by (a) US Government employee(s) and is in the public domain in the US.

This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Figure 1. — Neutralization antibody titers following vaccination. A, Swarmplot/boxplot of IC50 plotted over time before and after vaccination, second dose, and third dose. Boxplot shows median, lower/upper quartile, and extremes. B, Swarmplot/boxplot of fold-change (FC[IC50]) over pre-vaccination IC50 plotted over time after the first dose of vaccine. A values are derived from paired A test. Outliers, values further than 1.5 times the interquartile range (Q1–1.5^*IQR and Q₃+1.5*IQR), are shown beyond the boxplot. Subjects with COVID prior to first dose of vaccination were excluded in figure 1A because it artifactually lowers the fold-change. The 1- month time point was 1 month post third dose. The 12-month timepoint was 3 months post third dose.